Andrew Dudum

The company's insight was that many common health conditions — hair loss, erectile dysfunction, acne, anxiety — carry social stigma that prevents people from seeking treatment through traditional healthcare channels. By offering discreet, affordable online consultations and home-delivered treatments, Hims & Hers removed the friction from accessing care for these conditions. The company's growth has accelerated dramatically with the entry into weight management through compounded GLP-1 medications (semaglutide). During a period of severe supply shortages for branded Ozempic and Wegovy, compounding pharmacies (including Hims & Hers' affiliated pharmacies) were legally permitted to produce compounded versions at significantly lower prices. This created a massive new revenue stream, though the sustainability depends on FDA compounding regulations and the resolution of supply shortages. Hims & Hers operates a vertically integrated model: telehealth consultations (via its medical practice network), fulfillment through its own pharmacies, and direct-to-consumer marketing and subscription management. Key stock drivers include subscriber growth, GLP-1 compounding regulatory risk, average revenue per subscriber, customer acquisition costs, the transition to personalized treatments, and the competitive dynamics against Ro, Noom, and traditional healthcare providers entering the telehealth space.